Network Pharmacology of Turmeric Rhizome (Curcuma longa L.) as Antiinflamatory in Ulcerative Colitis

Abstract

Ulcerative colitis is an inflammatory bowel disease characterized by mucosal inflammation, starting from the rectum and can spread throughout the colon. This study aims to identify proteins involved in UC, determine the target proteins of turmeric rhizome compounds as anti-inflammatory, and analyze the pharmacological profile of turmeric rhizome chemical compounds against disease proteins. The method used was NP, with data collection of compounds from KNApSAcK and Phytochem. Protein targets were identified through STRING, PubChem, STP, SEA and SuperPRED, validated using UniProt and visualized using Cytoscape. profile visualization showed interactions between target proteins involved in the pathophysiology of UC, such as JAK2, JAK1, GATA3, STAT6, IL4R, IL4, IL13, IL12RG, IL10, IL2, IL5, TLR4, TLR5, TLR2, NOD2, MAF, and NFE2L2 with turmeric rhizome compounds. These compounds include curcumin, bisdemethoxycurcumin, limonene, quercetin, alpha pinene, cineole, demethoxycurcumin, ribitol, stigmasterol, and guaicol. This combination forms a pharmacological network that has the potential to address UC.